Jpmorgan Chase & CO Onconova Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ONTX
# of Institutions
25Shares Held
2.86MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA1.05MShares$616,7030.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA707KShares$417,0830.0% of portfolio
-
Black Rock Inc. New York, NY249KShares$146,8380.0% of portfolio
-
Geode Capital Management, LLC Boston, MA224KShares$132,2100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny218KShares$128,6750.0% of portfolio
About Onconova Therapeutics, Inc.
- Ticker ONTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,895,600
- Market Cap $12.3M
- Description
- Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...